Context: Despite its frequency, the polycystic ovary syndrome (PCOS) is still a difficult diagnosis in endocrinology, gynecology, and reproductive medicine. To help solve this issue, the Rotterdam consensus conference proposed to include the ultrasonographic follicle count as a new diagnostic criterion, in addition to hyperandrogenism and oligo-anovulation. Unfortunately, its assessment does not offer sufficient reliability worldwide.
Conclusions:
The serum AMH level is an accurate marker of the ovarian early antral follicle number and offers a good diagnostic potency. In situations where accurate ultrasonographic data are not available, AMH could thus be used instead of the follicle count A LTHOUGH THE POLYCYSTIC ovary syndrome (PCOS) is the most frequent endocrine disorder in women of reproductive age, its diagnosis remains one of the most challenging issues in endocrinology, gynecology, and reproductive medicine.
For many years, different combinations of clinical (irregular menstrual cycles, hirsutism, and acne), biological (elevated serum testosterone or androstenedione levels or increased LH/FSH ratio), and ultrasound (U/S) criteria have been proposed, with very little international consensus. Indeed, the conservative definition for PCOS that was issued from a conference held in the National Institutes of Health in 1990 (1) did not satisfy many authors because it omitted the U/S criteria. More recently, during another consensus conference held in Rotterdam in 2003 (2) it has been proposed to include in the definition of PCOS the U/S criteria that are considered at the present time as the most specific, namely an increased ovarian volume (Ͼ10 ml) and/or the presence of 12 or more follicles in each ovary measuring 2-9 mm (3).
Indeed, using a threshold of 12 for the follicle number per ovary (FNPO), we showed that 75% of PCOS patients were diagnosed whereas 99% of the normal women were under this cut off value (4) .
Many participants at the Rotterdam consensus conference felt that the introduction of those U/S criteria would help standardizing the diagnosis of PCOS worldwide. However, others are still reluctant, mainly because the counting of the FNPO may not be easy to obtain with sufficient reliability by every group, and also because it is still debated whether a FNPO greater than 12 is specific of polycystic ovaries (PCO) (5) . For these reasons, we investigated in this study whether the assay of the anti-Mü llerian hormone (AMH) could be a surrogate for the FNPO in the Rotterdam definition of PCOS. Indeed, increased AMH serum levels were found in PCOS patients, in close relationship with the excess of the 2-to 9-mm FNPO (6, 7) . This was expected because this member of the TGF␤ family is produced by the granulosa cells of early developing preantral and small antral follicles (8) , whose number is 2-to 3-fold in PCO compared with normal ovaries (4) . Therefore, providing it offers similar specificity and sensitivity, AMH would present itself as a biological marker for PCO that would be easier to obtain than FNPO and would avoid using U/S in some patients. We took the opportunity of having access to a new second-generation AMH ultrasensitive assay to check this hypothesis. 
Patients and Methods

Patient population
Controls. The control population consisted of 96 women who were referred to our department for in vitro fertilization because of tubal and/or male infertility. Exclusion criteria were a history of menstrual disturbances (i.e. cycle length either Ͻ25 d or Ͼ35 d), hirsutism, abnormal serum level of prolactin or androgens (i.e. serum testosterone above 0.7 ng/ml and/or ⌬4-androstenedione above 2.2 ng/ml), ovarian volume greater than 10 ml and FNPO greater than 12 at U/S, and hormonal treatment during the 3 months before the study.
Patients with PCOS. Seventy-three women were enrolled in this study. According to the Rotterdam criteria (2), the diagnosis of PCOS was based on the association of at least two of the three following criteria: 1) ovulatory disturbance, mainly oligomenorrhea or amenorrhea, 2) hyperandrogenism (HA) as defined either clinically by hirsutism (modified Ferriman and Gallwey score Ͼ 6), or severe acne/seborrhea, and/or biologically by a testosterone serum level greater than 0.7 ng/ml and/or ⌬4-androstenedione greater than 2.2 ng/ml, and 3) more than 12 follicles in the 2-to 9-mm range in each ovary at U/S and/or an ovarian volume higher than 10 ml. U/S examination was performed with a 7-MHz transvaginal transducer (Logic 400; General Electric, Milwaukee, WI). U/S measurements were taken in real time, according to a standardized protocol, as previously described (9) . This study was approved by the Institutional Review Board of the University Hospital of Lille. All patients and controls gave an informed consent before their inclusion in this study.
Hormonal immunoassays
Blood sampling was performed in the early follicular phase, between d 2 and 7 after the last menstrual period both in PCOS patients and in controls. In PCOS patients, the last menstrual period was either spontaneous or induced by the administration of didrogesterone (10 mg/d for 7 d). Any patient with at least one follicle with a diameter greater than 9 mm or a serum estradiol level above 80 pg/ml was excluded from the study. Serum AMH levels were assessed using the second-generation enzyme immunoassay AMH-EIA (reference A16507) provided by Immunotech (a Beckman Coulter company from Marseille, France) according to the supplier's instructions. A recombinant human AMH was used as a calibration standard to build a standard curve ranging from 0 -150 pmol/liter. Intra-and interassay coefficients of variation were less than 12.3 and 14.2%, respectively. The functional sensitivity (i.e. the lowest concentration of AMH that could be measured with an interassay coefficient of variation less than 20%) is 2.50 pmol/liter (Taieb, J., and P. Pigny, unpublished data). LH and FSH were measured using chemiluminescent two-site immunoassays on a multiparameter system (Axsym; Abbott Laboratories, Rungis, France) whereas testosterone was measured in duplicate using a RIA (Coat-a-Count, total testosterone kit) provided by Diagnostic Products Corp. (La Garenne Colombes, France). Androstenedione was also measured by RIA using the active androstenedione kit provided by Diagnostic Systems Laboratories (CergyPontoise, France).
Statistical methods
Receiver operating characteristic (ROC) curves were constructed to examine the diagnostic test performance, i.e. its capacity to discriminate between controls and patients with PCOS. Sensitivity (y-axis) against [1-specificity (x-axis)] was plotted at each threshold level, and the area under the curve (AUC) was computed by the nonparametric Wilcoxon test. AUC represents the probability of correctly identifying controls and patients with PCOS. A value of 0.5 means that the test result is no better than chance. Comparisons of two independent groups were performed using the Student t test for normally distributed variables and by MannWhitney test for variables not normally distributed. The Kruskal-Wallis nonparametric ANOVA was used for comparisons of AMH levels between subgroups of patients (n Ͼ 2). Significant relationships between AMH and the various parameters were evaluated by the nonparametric Spearman correlation coefficient. All statistical analyses were performed using Statview 4.5 (Abacus Concepts Inc., Berkeley, CA) and SPSS 11.5 (SPSS Inc., Chicago, IL).
Results
Clinical, biological, and U/S features of each population are shown in Table 1 . As expected, patients with PCOS had higher body mass index values and higher serum levels of LH, testosterone, and androstenedione than controls. There was a trend toward lower FSH values in PCOS patients than in controls. The mean serum AMH level was 3-fold higher in PCOS patients than in controls (P Ͻ 0.001) as already reported by ourselves with the previous first-generation assay (6) . Likewise, the mean 2-to 9-mm FNPO at U/S was 3-fold higher in PCOS patients than in controls (P Ͻ 0.001). It was significantly related to the serum AMH levels, both in controls (r ϭ 0.537; P Ͻ 0.01) and in patients (r ϭ 0.274; P Ͻ 0.05). AMH was also positively related to the serum testosterone level in both groups (r ϭ 0.225 and P Ͻ 0.03 in controls; r ϭ 0.360 and P Ͻ 0.003 in patients; see Fig. 1 ). No significant correlation was observed between FSH and AMH levels in PCOS patients.
The diagnostic potency of the AMH assay was tested by the ROC procedure (see Patients and Methods). As displayed in Fig. 2 , the area under the ROC curve for AMH reached a value of 0.851 (0.796 -0.905, 95% confidence interval). Several threshold values of serum AMH level were analyzed in terms of specificity and sensitivity from the ROC curve data. Table  2 showed that the best compromise between specificity (92%) and sensitivity (67%) was obtained with a cutoff value of 60 pmol/liter. This value is slightly higher than the 90th percentile of controls.
In PCOS patients, the mean serum level of AMH differed significantly by ANOVA (P Ͻ 0.05) between those presenting either with amenorrhea (n ϭ 9), oligoamenorrhea (n ϭ 44) or regular cycles (n ϭ 18), the former and the latter having the highest and the lowest values, respectively ( Table 3) . As expected, the 2-to 9-mm FNPO followed the same trend in Values are expressed as the mean with the 5th-95th percentile range in parentheses. NS, Nonsignificant.
these three subgroups (ANOVA, P Ͻ 0.05), whereas age did not exert a statistically significant effect (Table 3) . When the PCOS patients with abnormal cycles were gathered together (n ϭ 53), we observed that the AMH levels varied significantly according to the absence (n ϭ 12) or the presence (n ϭ 41) of HA, as defined by a serum level of testosterone above 0.7 ng/ml and/or androstenedione above 2.2 ng/ml and/or clinically by hirsutism (Fig. 3) . On the contrary, the 2-to 9-mm FNPO was not significantly different between HA-positive and HA-negative PCOS patients (Fig.  3) . Therefore, these data suggest that HA is associated with higher serum AMH levels in PCOS patients with irregular cycles.
Discussion
In this study, we investigated whether AMH measurement could be a valuable diagnostic marker of PCOS. Indeed, numerous studies in the literature suggest that AMH is a potential marker of the ovarian follicle pool. In 2003, Fanchin et al. (10) demonstrated that the antral follicle count was closely related to the serum AMH level on cycle d 3 in infertile women, in a stronger way than those obtained with other hormonal markers such as inhibin B, estradiol, or FSH. Later, several teams reported on a strong increase (2-to 4-fold) of serum AMH levels in PCOS patients, in close relationship with the increase in the small antral FN (6, 7). Moreover we showed that the correlation between AMH and the small antral follicle count also stands in normal women (6) . Thus, all these data led to the conclusion that AMH could be the best available biological marker of the ovarian early antral FN, both in fertile and infertile normoovulatory women and in PCOS patients. Moreover, it was recently demonstrated that the measurement of serum AMH levels was highly reproducible from one cycle to another, a fact that underlines its robustness as a biological marker of the ovarian follicle status (11) .
In this study, the diagnostic performance of AMH was assessed using the ROC curves. The AUC of serum AMH assay yielded a satisfying value of 0.851 (0.796 -0.907), lower however than the one obtained with the 2-to 9-mm follicle count (0.937) in our previous study (4) . With a cutoff value of 60 pmol/liter, the serum AMH level had a good specificity of 92% but a relatively poor sensitivity of 67%, meaning that a third of PCOS patients, as defined by the Rotterdam criteria, would be misdiagnosed if one used exclusively the measurement of serum AMH. With a sensitivity of 75% and a specificity of 100% for a cutoff value at 12 (4), the follicle count appears as a better diagnostic tool than AMH measurement, at least in our hands. However, it must be stressed that comparing both studies is somewhat artificial because the latter data were obtained in a different series of patients, using different inclusion criteria. Indeed, the comparison of the diagnostic performance between AMH and the 2-to 9-mm follicle count could not be done in the present study because the latter was used as inclusion and exclusion criteria (see Patients and Methods). Whatsoever, it can be proposed from the present data to perform an AMH assay in medical centers where the U/S count of small antral follicles is not available. Indeed the single measurement of AMH in the early follicular phase appeared to be a valuable surrogate for the FNPO and it could therefore be used in place of the U/S data in the Rotterdam definition.
However, it must be kept in mind that neither a high value of AMH nor a high FNPO is per se sufficient to ascertain PCOS. Both criteria need to be incorporated into the Rotterdam definition, and it indicates PCOS only if associated with HA and/or oligo-anovulation. In addition, as recommended by the Rotterdam consensus conference (2), it must be remembered that this classification can be used only after the step of exclusion of other etiologies. This is particularly important to allow distinguishing PCOS from other diseases that are accompanied by multifollicular ovaries at U/S (12), such as recovering anorexia nervosa or functional hypothalamic anovulation. The AMH assay is not helpful for solving this issue because we previously found increased serum AMH levels in functional hypothalamic anovulation patients (13) . This emphasizes the need for a careful exclusion diagnosis lying mainly on clinical history, before using the Rotterdam definition including either the FNPO or the serum AMH level. Lastly, we showed in this study that the serum AMH level was also strongly associated with the main phenotypic features of PCOS, namely ovulation disorder and HA. This is line with Laven et al. (7) , who also reported a positive correlation between the cycle duration, the serum androgens levels, and AMH in PCOS patients. Our results also agree with those of La Marca et al. (14) showing that amenorrheic women with PCOS had a higher mean serum AMH level than their oligomenorrheic counterparts. Altogether, these studies suggest that higher AMH levels are observed in PCOS patients in whom the process of terminal follicle maturation is the most impaired. Interestingly, we observed the same trend with the FNPO, in agreement with data obtained by others on ovarian cortical biopsies (15) . Moreover, we also showed that in patients with irregular cycles, the presence of HA was associated with a further increase of the AMH value, in agreement with the previous report of Eldar-Geva et al. (16) . This lends support to our hypothesis that AMH may be involved in the ovulatory disorder of PCOS patients (17) and may have effects distinct from HA, putatively through inhibition of the FSH-dependant cyclic recruitment (8) and/or aromatase activity (18) .
In conclusion, the assay of serum AMH in women with HA and/or oligo-anovulation could indicate to the clinicians the presence of PCO when reliable U/S is not available. Additional studies are warranted to confirm that AMH could also be a prognostic marker of the extent of the ovarian dysfunction in PCOS patients and, in particular, whether it can predict response to ovulation induction. Values are expressed as the mean with the SD in parentheses. NS, Nonsignificant.
FIG. 3. Box-and-whisker plots
showing the values of serum AMH levels (top) and 2-to 9-mm FN (bottom) in PCOS patients with irregular cycles according to the presence (n ϭ 41) or the absence (n ϭ 12) of HA (HAϩ and HAϪ, respectively). Horizontal small bars represent the 10 -90th percentile range, and the boxes indicate the 25-75th percentile range. The horizontal line in each box corresponds to the median. P value was assessed by the Mann-Whitney test.
